Benjamin A. H. Smith

Benjamin A. H. Smith

Auto-generated profile, based on publicly available information

Benjamin A. H. Smith

Stanford University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Cell
Verified
Journal Article
Closed access
RFRyan A. Flynn
Ryan A. Flynn
KPKayvon Pedram
Kayvon Pedram
SMStacy Malaker
Stacy Malaker
PBPedro J. Batista
Pedro J. Batista
BSBenjamin A.H. Smith
Benjamin A.H. Smith
CBCarolyn Bertozzi
Carolyn Bertozzi

18 January 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
BSBenjamin A. H. Smith
Benjamin A. H. Smith
CBCarolyn Bertozzi
Carolyn Bertozzi

3 April 2019 in Nature
Verified
Journal Article
Closed access
PDF file
JPJohn V. Pluvinage
John V. Pluvinage
MHMichael S. Haney
Michael S. Haney
BSBenjamin A. H. Smith
Benjamin A. H. Smith
JSJerry Sun
Jerry Sun
TITal Iram
Tal Iram
TWTony Wyss-Coray
Tony Wyss-Coray

13 January 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JTJohanna Theruvath
Johanna Theruvath
MMMarie Menard
Marie Menard
BSBenjamin A. H. Smith
Benjamin A. H. Smith
MLMiles H. Linde
Miles H. Linde
GCGarry L. Coles
Garry L. Coles
RMRobbie G. Majzner
Robbie G. Majzner

25 January 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SWSimon Wisnovsky
Simon Wisnovsky
LMLeonhard Möckl
Leonhard Möckl
SMStacy Malaker
Stacy Malaker
KPKayvon Pedram
Kayvon Pedram
GHGaelen T. Hess
Gaelen T. Hess
CBCarolyn Bertozzi
Carolyn Bertozzi
Glyco-immune checkpoint receptors, molecules that inhibit immune cell activity following binding to glycosylated cell-surface antigens, are emerging as attractive targets for cancer immunotherapy. Defining biologically relevant ligands that bind and activate such receptors, however, has historically been a significant challenge. Here, we present a CRISPRi genomic screening strategy that allowed unbiased identification of the key genes required for cell-surface presentation of glycan ligands on leukemia cells that bind the glyco-immune checkpoint receptors Siglec-7 and Siglec-9. This approach revealed a selective interaction between Siglec-7 and the mucin-type glycoprotein CD43. Further work identified a specific N-terminal glycopeptide region of CD43 containing clusters of disialylated O-glycan tetrasaccharides that form specific Siglec-7 binding motifs. Knockout or blockade of CD43 in leukemia cells relieves Siglec-7-mediated inhibition of immune killing activity. This work identifies a potential target for immune checkpoint blockade therapy and represents a generalizable approach to dissection of glycan–receptor interactions in living cells. Significance Cancer cells are frequently coated with chains of sugar molecules (glycans) that bind to inhibitory immune receptors, leading to suppression of anticancer immunity. While blocking these interactions may be therapeutically beneficial, the specific glycoprotein ligands that engage such receptors are often complex and difficult to characterize. To solve this problem, we used unbiased genome-wide screening to identify genes required for cell-surface presentation of ligands that bind members of the Siglec immune receptor family. This approach led to identification of the glycoprotein CD43 as a highly specific ligand for Siglec-7. Blocking the interaction between CD43 and Siglec-7 sensitizes leukemia cells to immune cell lysis, implying that targeting the CD43/Siglec-7 checkpoint could be therapeutically beneficial.

11 July 2022 in Nature Cancer
Verified
Journal Article
Open access
PDF file
NMNathaniel W. Mabe
Nathaniel W. Mabe
MHMin Huang
Min Huang
GDGuillermo N. Dalton
Guillermo N. Dalton
GAGabriela Alexe
Gabriela Alexe
DSDaniel A. Schaefer
Daniel A. Schaefer
RMRobbie G. Majzner
Robbie G. Majzner
Immunotherapy with anti-GD2 antibodies has advanced the treatment of children with high-risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms of resistance to anti-GD2 therapy. Here, we show that reduced GD2 expression was significantly correlated with the mesenchymal cell state in neuroblastoma and that a forced adrenergic-to-mesenchymal transition (AMT) conferred downregulation of GD2 and resistance to anti-GD2 antibody. Mechanistically, low-GD2-expressing cell lines demonstrated significantly reduced expression of the ganglioside synthesis enzyme ST8SIA1 (GD3 synthase), resulting in a bottlenecking of GD2 synthesis. Pharmacologic inhibition of EZH2 resulted in epigenetic rewiring of mesenchymal neuroblastoma cells and re-expression of ST8SIA1, restoring surface expression of GD2 and sensitivity to anti-GD2 antibody. These data identify developmental lineage as a key determinant of sensitivity to anti-GD2 based immunotherapies and credential EZH2 inhibitors for clinical testing in combination with anti-GD2 antibody to enhance outcomes for children with neuroblastoma.